UBS Group’s Allena Pharmaceuticals ALNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-83,827
| Closed | -$16K | – | 11689 |
|
|
2022
Q2 | $16K | Buy |
83,827
+69,893
| +502% | +$10.8K | ﹤0.01% | 7263 |
|
|
2022
Q1 | $4K | Sell |
13,934
-46,065
| -77% | -$19.1K | ﹤0.01% | 9403 |
|
|
2021
Q4 | $35K | Buy |
59,999
+22,313
| +59% | +$17.4K | ﹤0.01% | 7247 |
|
|
2021
Q3 | $34K | Buy |
37,686
+35,186
| +1,407% | +$34.5K | ﹤0.01% | 6655 |
|
|
2021
Q2 | $3K | Sell |
2,500
-7,274
| -74% | -$8.81K | ﹤0.01% | 8894 |
|
|
2021
Q1 | $13K | Buy |
+9,774
| New | +$16.3K | ﹤0.01% | 7768 |
|
|
2020
Q2 | – | Sell |
-7,757
| Closed | -$7K | – | 8537 |
|
|
2020
Q1 | $7K | Buy |
+7,757
| New | +$15.5K | ﹤0.01% | 7185 |
|
|
2019
Q4 | – | Sell |
-3,258
| Closed | -$13K | – | 8554 |
|
|
2019
Q3 | $13K | Buy |
3,258
+3,231
| +11,967% | +$13.9K | ﹤0.01% | 7021 |
|
|
2019
Q2 | $0 | Buy |
+27
| New | +$148 | ﹤0.01% | 8298 |
|
|
2019
Q1 | – | Sell |
-5,488
| Closed | -$30K | – | 8358 |
|
|
2018
Q4 | $30K | Buy |
5,488
+2,708
| +97% | +$23.3K | ﹤0.01% | 6492 |
|
|
2018
Q3 | $30K | Sell |
2,780
-865
| -24% | -$9.51K | ﹤0.01% | 6554 |
|
|
2018
Q2 | $47K | Buy |
+3,645
| New | +$52.6K | ﹤0.01% | 6021 |
|
|
2018
Q1 | – | Sell |
-1,974
| Closed | -$20K | – | 8300 |
|
|
2017
Q4 | $20K | Buy |
+1,974
| New | +$24.3K | ﹤0.01% | 6570 |
|
Other funds holding ALNA
UBS Group's ALNA Position: Q3 2022 in Review
UBS Group sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 83,827 shares — an estimated $16K sold.
UBS Group first reported a position in ALNA in Q4 2017 and held it in 13 quarters. The position peaked at $47K in Q2 2018. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.
- UBS Group reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 83,827 Allena Pharmaceuticals shares in Q3 2022, an estimated $16K.
- UBS Group first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 13 quarters.
- UBS Group's Allena Pharmaceuticals position peaked at $47K in Q2 2018.
- 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.